Bayer forms gene editing partnership with CRISPR Therapeutics
0
FRANKFURT (Reuters) - Bayer will spend 325 million euros ($353 million) on research into a promising new gene editing technology as part of a joint venture with biotech firm CRISPR Therapeutics.